BGM Group (BGM) EV/Sales: History & Chart

BGM Group Ltd.(BGM)

Drug Manufacturers - Specialty & Generic · Chengdu, SIC

$8.81-0.54 (-5.78%)

Delayed quote: Oct 6, 2026, 9:39 AM EDT

About BGM Group Ltd.

Operating from Chengdu, People's Republic of China, BGM Group Ltd. engages in the manufacturing and supply of active pharmaceutical ingredients (APIs), traditional Chinese medicine (TCM) derivatives, and various other related products across China. The company's pharmaceutical portfolio includes an array of licorice-based items: Gan Di Xin, an oral medication for cough and expectorant relief; Qilian Shan Licorice Extract, serving as a raw material for pharmaceutical firms to produce conventional licorice tablets; and Qilian Shan licorice liquid extract, a key ingredient utilized by medical preparers for crafting compound licorice oral solutions. BGM also provides Qilian Shan oxytetracycline tablets, formulated to prevent and treat a range of ailments in poultry (chickens, turkeys), livestock (cattle, swine), and humans, in addition to Qilian Shan oxytetracycline APIs for use by pharmaceutical manufacturers. Beyond APIs, the company produces TCM derivatives such as Ahan antibacterial paste, which is designed for managing stubborn chronic skin conditions. Its diverse offerings also encompass heparin products, including heparin sodium preparations essential for pharmaceutical companies developing treatments for cardiovascular and cerebrovascular diseases, as well as hemodialysis applications. Furthermore, BGM supplies natural food products like Zhu Xiaochang sausage casings for culinary use. In the agricultural sector, it offers Xiongguan organic fertilizers, which enhance crop yields, improve soil chemical characteristics, and alleviate compaction, alongside Xiongguan organic-inorganic compound fertilizers engineered to promote superior plant development. Established in 2019, the company operated as Qilian International Holding Group Limited until adopting its current name, BGM Group Ltd, in October 2024.

Chengdu, SIC

298 employees

www.bgmgroupltd.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Chen Xin

View full financials

NAME	MARKET CAP	EV/SALES RATIO	TTM	3Y	5Y
BGM Group Ltd. (BGM)	$111.78M	N/A	N/A	N/A	N/A
Genelux Corporation (GNLX)vs ›	$117.03M	13783.69x	11863.26x	8138.14x	6150.74x
Caribou Biosciences, Inc. (CRBU)vs ›	$118.52M	11.86x	18.19x	13.45x	23.44x
Foghorn Therapeutics Inc. (FHTX)vs ›	$116.84M	2.50x	9.70x	9.36x	78.10x
Aardvark Therapeutics, Inc. Common Stock (AARD)vs ›	$115.66M	N/A	N/A	N/A	N/A
Insight Molecular Diagnostics Inc. (IMDX)vs ›	$120.80M	63.27x	54.20x	33.22x	26.89x
LENZ Therapeutics, Inc. (LENZ)vs ›	$114.76M	4.22x	33.01x	61.00x	61.00x
Coya Therapeutics, Inc. (COYA)vs ›	$114.47M	N/A	52.04x	28.07x	28.07x
Lucid Diagnostics Inc. (LUCD)vs ›	$113.55M	19.29x	23.83x	20.50x	102.56x
TuHURA Biosciences, Inc. (HURA)vs ›	$122.20M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EV/SALES RATIO

TTM

BGM Group Ltd. (BGM)

$111.78M

N/A

Genelux Corporation (GNLX)vs ›

$117.03M

13783.69x

11863.26x

8138.14x